not available, selection of patients for EGFR-TKI treatment canbebasedonpatient-relatedfactors,suchasfemalegender, non-smoking status, Asian ethnicity, and adeno-or bronchioloalveolar carcinoma histology. Such selection is associated withfavourableresponsesinupto30%ofpatients [5, 6] .
The success of EGFR-TKIs in these subpopulations of NSCLCpatientshasbeenbittersweet.Certainlythehighresponse rates and remarkable responses with no identifiable or minimal residual disease are exiting. However, these can hardlybeseenascure.Evendramaticresponderseventually relapse,andthemechanismofacquiredresistanceisunclear. At recent conferences, several molecular strategies to overcomesuchresistancehavebeenhypothesizedwhichmayprovideamoresustainable'cure' [2] [3] [4] [5] [6] [7] .
ThepaperofLevchenkoetal. [1] describestheaspectof local consolidation therapy to overcome the problem of acquiredresistance.TosustainamajorresponsetoEGFR-TKIs inpatientswith'oligometastatic'NSCLC,surgicalresectionof the primary tumour (with regional lymph nodes) and a solitarymetastasismaythereforebeconsidered.
However,themajorproblemofthisstrategyistheidentificationofpatientswhomaybenefitfromsurgicalresection. Selection is highly dependent on the reliability of imaging, notonlytoevaluatediseaseextentbutalsoforresponseassessment.DisseminationinNSCLCisoftenmorewidespread than the available imaging techniques show us. Even after completeresectionof'early-stage'NSCLC,long-termsurvival ratesaredisappointing.TheInternationalAssociationforthe Study of Lung Cancer (IASLC) staging project reported 5-yearsurvivalof56and38%forpathologicallystagedN0and N1disease,respectively [8] .Recurrencesmostoftenariseat distant sites, confirming the idea that even early-stage operableNSCLCisoftena(micro)metastaticdiseaseatdiagnosis.
Positron emission tomography (PET) has shown to improve imaging accuracy especially in the identification of Clinicians who treat patients with lung cancer are familiar withthefactthatnon-smallcelllungcancer(NSCLC)isaheterogeneousdisease.Untilrecently,wecouldonlyrelyonclassichistopathologicalandradiologicalstaging,andwelacked the ability to use molecular profiles to classify patients into more clinically meaningful subgroups. Novel therapies such asepidermalgrowthfactorreceptortyrosinekinaseinhibitors (EGFR-TKIs)forNSCLChavehadatransformingeffecton bothlungcancerresearchandclinicalcare.
In this issue of OnkOlOgie, the article by Levchenko and colleaguesfocusesonup-fronttreatmentwithgefitinibinpatients with advanced NSCLC, followed by surgery [1] . The report describes two patients with EGFR mutated tumours showingremarkableresponseswithin2-3monthsofgefitinib treatment. Surgery was performed for minimal residual disease. Although only two cases are described, the treatment approachisinterestingandrequiresfurtherdiscussion.
Two to four courses of chemotherapy for NSCLC may yield response rates of up to 40-50%, but (near) complete responses are rare [2] . Small-molecule EGFR-TKI, such as gefitinib and erlotinib, are able to induce swift and remarkableresponsesinselectedpatients.Gefitinibanderlotinibcan beorallyadministeredandblockthetyrosinekinasedomain oftheEGFR,therebyinhibitingdownstreamsignallingpathways involved in cell proliferation, angiogenesis, invasion, metastasis and prevention of apoptosis. (Near) complete responsesanddramaticsymptomaticreliefhavebeendescribed repeatedly.Respondersarepresumedtobethosewithadistinct tumour biology that relies heavily upon signalling via EGFR.Theyrepresentasubgroupofaround10-20%ofthe Europeanpatientpopulation [2] [3] [4] .
Highresponserates(>70%)canbeachievedwhenselection ofpatientsisappliedthroughmolecularEGFR(andKRAS) mutation analysis, which requires pre-treatment tumour tissue [5] . If pre-treatment tissue or EGFR mutation testing is 628 Onkologie2009;32:627-628
Klomp/Kappers distant NSCLC spread. As Levchenko et al. appropriately discuss, some studies indicate that surgical resection may be associated with favourable survival in selected patients with stageIVNSCLC.Inthisgroupofpatientswithso-calledoligometastatic disease, outcome is highly dependent on selection.SincePETcanidentify(theextentof)distantmetastatic diseasemoreaccuratelythanCT,evaluationbyPET/CTwill probablyimproveselectionofpatientsconsideredforsurgical resection.
Clinicalobservationshavebeencrucialinfurtherresearch concerningthebiologicalbasisofthedramaticresponsesseen in patients treated with EGFR-TKIs. Despite a better understanding of the molecular heterogeneity of tumours and the complex multidirectional interactions between signalling pathways, the challenge remains not only to establish optimalcombinationsofnovelagentsthatareeffectiveandwell tolerated, but also to integrate novel therapies with other treatmentmodalitiesintomoreeffectivetreatmentstrategies. Local treatment, such as surgical resection or radiotherapy, may be considered for consolidation therapy after major responsetoEGFR-TKIs,eveninoligometastaticdisease.How toselectpatientsforsuchtreatmentsremainsanopenquestion.Carefulclinicalobservationsaswellasbiologicalstudies could help us to devise optimal treatment strategies for this specialsubgroupofpatients.
